Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 13/20 | 0.34 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079940 | 1.00 | AURKA (0.36) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL3067808 | 0.95 | AURKA (0.37) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL3067804 | 0.95 | AURKA (0.37) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL13093747 | 0.91 | AURKA (0.35) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL3066301 | 0.90 | AURKA (0.37) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL3066308 | 0.90 | AURKA (0.37) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL3068665 | 0.89 | AURKA (0.41) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL3068670 | 0.89 | AURKA (0.41) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL3079927 | 0.89 | MAP3K7 (0.39) | AURKACHEK1EGFRMAP3K7TAB1 | |
| SCHEMBL3079930 | 0.89 | MAP3K7 (0.39) | AURKACHEK1EGFRMAP3K7TAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267749-A1 | TRISUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMS | AURKA 2963/4885CHEK1 915/4885EGFR 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.